Welcome!

News Feed Item

The Global Market for Stem Cells

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Global Market for Stem Cells

 http://www.reportlinker.com/p02274672/The-Global-Market-for-Stem-Cells.html

This BCC Research report provides detailed market, technology, and industry analyses to quantify and qualify the global market for prescription drug products. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018.

Use this report to:
- Quantify and qualify the stem cell research market for prescription drug products.
- Receive information about stem cell technology and its practical applications.
- Understand how the regulatory environment, healthcare policies, demographics, and other factors directly affect the stem cell-related drug market.
- Learn about the nature and structure of the stem cell industry along with profiles of the leading companies.

Highlights
- BCC Research projects that the global stem cell market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 3.6% from 2013 through 2018.
- The Americas is the largest region of global stem cell market, with a market share of about $2.0 billion in 2013. The region is projected to increase to nearly $3.9 billion by 2018, with a CAGR of 13.9% for the period of 2013 to 2018.
- Europe is the second largest segment of the global stem cell market and is expected to grow at a CAGR of 13.4% reaching about $2.4 billion by 2018 from nearly $1.4 billion in 2013.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription drug products.
Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and
considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the stem cell-related drug market.
The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market.

REASONS FOR DOING THE STUDY
Although products based on stem cells do not yet form an established market, unlike some other potential applications of bioscience, stem cell technology has already
produced a number of significant products in important therapeutic areas. This is because the possibilities for successful stem cell therapy are almost beyond estimation,
and the urgent need to develop this field is overriding the established, step-by-step approach to proceeding from basic science to practical applications. The potential
scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its practical applications so far, evaluate the participating
companies and look to its future.

SCOPE OF REPORT
This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global
terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2014-dollar value without attempting to predict the effect of inflation/deflation.
Therapeutic categories quantified and forecast include cancer, CNS diseases, infections and cardiovascular. Major country markets in three regions—Americas, Europe and
Asia—are analyzed and forecast, with a summary for the rest of the world.

METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. Primary research includes interviews with leading individuals in stem cell companies
and industry associations. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources
consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically
assessed by BCC Research.

INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management
executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in
marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES
Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also reviewed.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
MARKET ANALYSES AND FORECASTS 2
METHODOLOGY 3
INTENDED AUDIENCE 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 3
BCC RESEARCH WEBSITE 3
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
DEFINITIONS 6
APPLICATIONS 6
RESEARCH AND COMMERCIALIZATION 6
FUNDING 7
MARKET 7
SUMMARY TABLE GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2018
($ MILLIONS) 8
SUMMARY FIGURE GLOBAL STEM CELL MARKET AND FORECASTS, 2012-2018 ($
MILLIONS) 8
CHAPTER 3 OVERVIEW 10
CELLS 10
STEM CELLS 10
FIGURE 1 EARLY DEVELOPMENT OF EMBRYO 10
INDUCED PLURIPOTENT STEM CELLS 13
hpSCS 14
THE CANCER PROBLEM 15
CANCER STEM CELLS-A WIDER TOPIC 15
CHAPTER 4 STEM CELL RESEARCH 19
HISTORY 19
EMBRYONIC STEM CELLS 20
Growth and Identification of ESCs 20
Stimulating ESCs to Differentiate 21
NEW CELL LINE 21
ADULT STEM CELLS 22
Mesenchymal Stem Cells (MSCs) 22
Haematopoietic Stem Cells (HSCs) 23
Neural Stem Cells (NSCs) 23
Endothelial Progenitor Cells (EPCs) 23
Epithelial Stem Cells (ESCs) 23
Very Small Embryonic-Like Cells (VSELs) 23
CORD BLOOD STEM CELLS 23
INDUCED PLURIPOTENT STEM CELLS (IPSCS) 24
Nuclear Reprogramming 24
CELL-BASED THERAPEUTICS 25
EMBRYONIC-DERIVED STEM CELLS 25
ADULT/PROGENITOR-DERIVED STEM CELLS 26
ENGINEERED SCS FOR TRANSPLANTATION 26
THERAPEUTIC STEM CELL BANKING 27
STEM CELL-BASED BIOMEDICAL RESEARCH 28
TABLE 1 STEM CELL RESEARCH CENTERS 28
REGULATION OF STEM CELL RESEARCH 30
AUSTRALIA 30
BRAZIL 31
CANADA 31
CHINA 31
FRANCE 31
GERMANY 32
INDIA 32
IRELAND 32
ISRAEL 33
ITALY 33
JAPAN 33
SOUTH KOREA 33
SPAIN 33
SWEDEN 34
UNITED KINGDOM 34
UNITED STATES 34
California 34
Massachusetts 35
Michigan 35
New Jersey 35
New York 35
FDA APPROACH 35
EUROPEAN UNION 35
PRACTICALITIES OF STEM CELL RESEARCH AND PRODUCTION 36
STEM CELL PRODUCTION 36
STEM CELL ACQUISITION 37
Characterization and Expansion 37
Maintenance and Storage 38
STEM CELL PRODUCTION ECONOMICS 39
Customized Therapy 39
Banks 40
NOVEL STEM CELL PRODUCTION DEVELOPMENTS 40
ISOLATION AND ENGINEERING 41
Adult Stem Cells 41
Embryonic Stem Cells 42
Induced Pluripotent Stem Cells 43
STEM CELL BANKING 44
ISCBI PROJECT 44
TABLE 2 COUNTRIES ENGAGED IN THE ISCBI PROGRAM 45
CHAPTER 5 STEM CELL APPLICATIONS 48
REGENERATIVE MEDICINE 48
CURRENT APPLICATIONS OF STEM CELL THERAPY 51
CANCER 51
Hematopoiesis (Blood Cell Formation) 51
AMYOTROPHIC LATERAL SCLEROSIS 52
PARKINSON'S DISEASE 53
SPINAL CORD INJURY 54
ALZHEIMER'S DISEASE 56
STROKE 57
HEART DISEASE 59
Doubts Expressed 61
PERIPHERAL ARTERIAL DISEASE 61
TYPE 1 DIABETES 63
ORTHOPEDIC REPAIR 64
LIVER FAILURE 65
GRAFT-VERSUS-HOST DISEASE 66
LUNG DISEASE 67
STATUS OF STEM CELL CLINICAL TRIALS 67
Prochymal-stem Cell Therapy 68
Prochymal-Crohn's Disease and Gastrointestinal Injury from
Radiation 68
Mesenchymal Precursor Cell (MPC) Product—Stem Cell Therapy
(Orphan Drug) 68
MyoCell-Stem Cell Therapy 69
ixmyelocel-T-Stem Cell Therapy (Fast Track) 69
StemEx (carlecortemcel-L)—Stem Cell Therapy (Orphan Drug) (Fast
Track) 69
GSK 2696273-Stem Cell Therapy 70
Adult Autologous Stem Cell Therapy (Renew)—Stem Cell Therapy 70
CHAPTER 6 STEM CELL PATENTS 73
GENERAL BACKGROUND ON PATENTS 73
STEM CELL PATENTS 74
PATENTABILITY OF STEM CELL LINES 74
INDIVIDUAL COUNTRY POLICIES 75
UNITED STATES 75
CANADA 75
EPC 75
UNITED KINGDOM 75
GERMANY 76
JAPAN 76
CHINA 76
iPS Cells 76
TABLE 3 IPS-RELATED PATENTS (YAMANAKA, 2011) 77
TABLE 4 CLASSIFICATION OF STEM CELL PATENTS 78
CHAPTER 7 STEM CELL MARKETS 80
MARKETS FOR STEM CELLS 80
MARKET DRIVERS 80
Healthcare 80
TABLE 5 HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES 82
Biotechnology 83
Pharmaceutical 84
MARKET OPPORTUNITIES BY THERAPEUTIC CLASS 85
CANCER 85
Other Cancers 86
CARDIOVASCULAR DISEASE 86
Myocardial Infarction 88
TABLE 6 EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD 89
CENTRAL NERVOUS SYSTEM DISEASE 89
Spinal Cord Injury (SCI) 90
TABLE 7 STATISTICS FOR SCI WORLDWIDE, 2011 90
Neurodegenerative Diseases 91
TABLE 8 NEURODEGENERATIVE DISEASES WORLDWIDE, 2011 (MILLIONS) 91
DIABETES MELLITUS 92
TABLE 9 STATISTICS FOR DIABETES IN THE U.S., 2014 92
TABLE 10 GLOBAL MARKET FOR DIABETES MELLITUS TREATMENTS AND DEVICES,
THROUGH 2018 ($ BILLIONS) 93
SKELETAL SYSTEM 94
GLOBAL MARKET ESTIMATES AND FORECASTS 95
TABLE 11 GLOBAL STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 95
REGIONAL AND NATIONAL MARKET ANALYSIS 95
AMERICAS 95
TABLE 12 AMERICAS STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 95
U.S. 96
TABLE 13 POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES 96
TABLE 14 THE U.S. STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 97
TABLE 15 THE U.S. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 98
TABLE 16 THE U.S. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 98
Canada 98
TABLE 17 CANADA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 99
TABLE 18 CANADA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 99
TABLE 19 CANADA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 100
Brazil 100
TABLE 20 BRAZIL'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 101
TABLE 21 BRAZIL'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 101
TABLE 22 BRAZIL'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 101
Mexico 102
TABLE 23 MEXICO'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 102
TABLE 24 MEXICO'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 102
EUROPE 103
TABLE 25 EUROPEAN STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 103
Market Opportunities by Disease Category 104
TABLE 26 STATISTICS FOR CVD IN EUROPE, 2012 104
TABLE 27 RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN
COUNTRIES, 2012 (NO. OF DEATHS PER 100,000 CASES) 104
TABLE 28 STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2013 105
TABLE 29 STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT
EUROPEAN COUNTRIES, 2011 105
TABLE 30 PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN
COUNTRIES, 2013 106
France 106
TABLE 31 FRANCE'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 106
TABLE 32 FRANCE'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 106
TABLE 33 FRANCE'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 107
Germany 107
TABLE 34 GERMANY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 107
TABLE 35 GERMANY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 108
TABLE 36 GERMANY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 108
Italy 108
TABLE 37 ITALY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 109
TABLE 38 ITALY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 109
TABLE 39 ITALY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 109
Spain 109
TABLE 40 SPAIN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 111
TABLE 41 SPAIN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 111
TABLE 42 SPAIN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 111
United Kingdom 111
TABLE 43 U.K.'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 112
TABLE 44 U.K.'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 112
TABLE 45 U.K.'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 113
ASIA 113
Market Opportunities by Disease Category 113
TABLE 46 STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011 113
TABLE 47 EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES 114
TABLE 48 ASIA'S STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 114
Japan 114
TABLE 49 JAPAN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 116
TABLE 50 JAPAN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 116
TABLE 51 JAPAN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 116
China 116
TABLE 52 CHINA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 119
TABLE 53 CHINA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 120
TABLE 54 CHINA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 120
India 120
TABLE 55 POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA 121
TABLE 56 INDIA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 121
TABLE 57 INDIA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 122
TABLE 58 INDIA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 122
REST OF WORLD 122
TABLE 59 REST OF WORLD STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 122
CHAPTER 8 COMPANY PROFILES 124
3DM 125
AASTROM BIOSCIENCES INC. 125
ADVANCED CELL TECHNOLOGY INC. 126
ALDAGEN INC. 127
ANGIOBLAST SYSTEMS 127
ARTERIOCYTE 128
ATHERSYS INC. 128
BEIKE BIOTECHNOLOGY CO., LTD. 129
BIOHEART INC. 130
BIOTIME INC. 131
BRAINSTORM CELL THERAPEUTICS INC. 132
CAPRICOR INC. 133
CARDIO3 BIOSCIENCES S.A. 134
CELLARTIS AB 135
CELLERANT THERAPEUTICS INC. 136
CELLERIX SA 137
CELLULAR DYNAMICS INTERNATIONAL 138
CYTORI THERAPEUTICS INC. 138
EPISTEM LTD. 140
FORTICELL BIOSCIENCE INC. 140
GAMIDA CELL, LTD. 141
GLOBALSTEM 142
HYBRID ORGAN GMBH 143
INTELLICELL BIOSCIENCES INC. 143
INTERNATIONAL STEM CELL CORP. 144
JUVENTAS THERAPEUTICS INC. 145
MEDISTEM INC. 146
MESOBLAST LTD. 147
NEOSTEM INC. 148
NEURALSTEM 149
NEUROGENERATION 149
OSIRIS THERAPEUTICS INC. 150
PHARMASTEM THERAPEUTICS INC. 151
PLUREON CORP. 151
PRIMEGEN BIOTECH LLC 151
RENEURON GROUP 152
RHINOCYTE INC. 153
STEM CELLS INC. 153
STEMCELL TECHNOLOGIES SARL 154
STEM CELL THERAPEUTICS CORP. 155
STEMEDICA CELL TECHNOLOGIES INC. 156
STEMINA BIOMARKER DISCOVERY INC. 156
STEMPEUTICS RESEARCH PVT. LTD. 157
TIGENIX NV 158
TRISTEM CORP. 159
VERASTEM INC. 160
VERISTEM TECHNOLOGIES 160
VIACYTE 161
VITRO DIAGNOSTICS INC. 162
WICELL RESEARCH INSTITUTE 162
XPAND BIOTECHNOLOGY BV 163
CHAPTER 9 APPENDIX 1: GLOSSARY 165
CHAPTER 10 APPENDIX 2: SIGNIFICANT STEM CELL RESEARCH PATENTS 172
TABLE 60 SIGNIFICANT STEM CELL RESEARCH PATENTS 172

LIST OF TABLES

SUMMARY TABLE GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2018 ($
MILLIONS) 8
TABLE 1 STEM CELL RESEARCH CENTERS 28
TABLE 2 COUNTRIES ENGAGED IN THE ISCBI PROGRAM 45
TABLE 3 IPS-RELATED PATENTS (YAMANAKA, 2011) 77
TABLE 4 CLASSIFICATION OF STEM CELL PATENTS 78
TABLE 5 HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES 82
TABLE 6 EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD 89
TABLE 7 STATISTICS FOR SCI WORLDWIDE, 2011 90
TABLE 8 NEURODEGENERATIVE DISEASES WORLDWIDE, 2011 (MILLIONS) 91
TABLE 9 STATISTICS FOR DIABETES IN THE U.S., 2014 92
TABLE 10 GLOBAL MARKET FOR DIABETES MELLITUS TREATMENTS AND DEVICES,
THROUGH 2018 ($ BILLIONS) 93
TABLE 11 GLOBAL STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 95
TABLE 12 AMERICAS STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 95
TABLE 13 POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES 96
TABLE 14 THE U.S. STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 97
TABLE 15 THE U.S. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 98
TABLE 16 THE U.S. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 98
TABLE 17 CANADA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 99
TABLE 18 CANADA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 99
TABLE 19 CANADA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 100
TABLE 20 BRAZIL'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 101
TABLE 21 BRAZIL'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 101
TABLE 22 BRAZIL'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 101
TABLE 23 MEXICO'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 102
TABLE 24 MEXICO'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 102
TABLE 25 EUROPEAN STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 103
TABLE 26 STATISTICS FOR CVD IN EUROPE, 2012 104
TABLE 27 RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN
COUNTRIES, 2012 (NO. OF DEATHS PER 100,000 CASES) 104
TABLE 28 STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2013 105
TABLE 29 STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT EUROPEAN
COUNTRIES, 2011 105
TABLE 30 PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN
COUNTRIES, 2013 106
TABLE 31 FRANCE'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 106
TABLE 32 FRANCE'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 106
TABLE 33 FRANCE'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 107
TABLE 34 GERMANY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 107
TABLE 35 GERMANY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH
2018 ($ MILLIONS) 108
TABLE 36 GERMANY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018
($ MILLIONS) 108
TABLE 37 ITALY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 109
TABLE 38 ITALY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 109
TABLE 39 ITALY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 109
TABLE 40 SPAIN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 111
TABLE 41 SPAIN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 111
TABLE 42 SPAIN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 111
TABLE 43 U.K.'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 112
TABLE 44 U.K.'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 112
TABLE 45 U.K.'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 113
TABLE 46 STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011 113
TABLE 47 EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES 114
TABLE 48 ASIA'S STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 114
TABLE 49 JAPAN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 116
TABLE 50 JAPAN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 116
TABLE 51 JAPAN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 116
TABLE 52 CHINA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 119
TABLE 53 CHINA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018
($ MILLIONS) 120
TABLE 54 CHINA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 120
TABLE 55 POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA 121
TABLE 56 INDIA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS) 121
TABLE 57 INDIA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 122
TABLE 58 INDIA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($
MILLIONS) 122
TABLE 59 REST OF WORLD STEM CELL MARKET, THROUGH 2018 ($ MILLIONS) 122
TABLE 60 SIGNIFICANT STEM CELL RESEARCH PATENTS 172

LIST OF FIGURES

SUMMARY FIGURE GLOBAL STEM CELL MARKET AND FORECASTS, 2012-2018 ($
MILLIONS) 8
FIGURE 1 EARLY DEVELOPMENT OF EMBRYO 10

To order this report: The Global Market for Stem Cells
http://www.reportlinker.com/p02274672/The-Global-Market-for-Stem-Cells.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.